Command Palette

Search for a command to run...

MANKIND

₹2646.3+0.30%
Market Cap
₹1,08,890.29 Cr
Stock P/E
55.61
ROCE
18.32%
ROE
16.98%
Book Value
₹0.00

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Others

Financials

YoY Net Sales
EPS Growth
Operating Margin

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Mankind Pharma Ltd. showcases strong profitability and growth relative to its peers, while maintaining low debt levels, making it an attractive pick in the Pharmaceuticals & Drugs industry. However, it has a relatively high valuation compared to its growth prospects, suggesting a balanced outlook with potential caution for new investors.

Key Points
  • • Mankind Pharma has the highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).
  • • Dr. Reddy's Laboratories ranks highest in profitability metrics like ROE (21.76%) and EBITDA margin (27.09%).
  • • Mankind has a low debt-equity ratio (0.021), indicating strong financial stability.
Top Performers
Mankind Pharma Ltd.

Highest revenue growth YoY (18.12%) and strong EPS growth (48.24%).

Dr. Reddy's Laboratories Ltd.

Highest ROE (21.76%) and significant profitability with low valuation metrics.

Cipla Ltd.

Best valuation attractiveness with a low PE (23.73) and high profitability.

Explore
Watchlists
Chat
Portfolio